Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Guardado en:
Autores principales: | Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
por: Piergiuseppe Agostoni, et al.
Publicado: (2019) -
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
por: Zoltán Papp, et al.
Publicado: (2020) -
Role of Levosimendan in acute decompensated heart failure
por: V.K. Katyal, et al.
Publicado: (2021) -
Escalating incidence of infective endocarditis in Europe in the 21st century
por: Nandan S Anavekar, et al.
Publicado: (2021) -
The DAPA Trial in the Context of Previous Prophylactic ICD Landmark Trials
por: Danielle Haanschoten, et al.
Publicado: (2021)